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ATROPINE USE IN CHILDREN 
AFTER NERVE GAS EXPOSURE
©2003.  Photo Courtesy of 
Meridian Medical Technologies, Inc.
F ollowing the FDA’s approval of a
pediatric dosage Atropen®, the
Pediatric Expert Advisory Panel was
asked to review the existing guidelines
and recommendations regarding the
treatment of children exposed to nerve
agents and the Mark-1 Kit; review the
new literature on pediatric nerve agent
exposure; and to develop recommenda-
tions and guidelines for this new device
including modifications to the existing
recommendations and guidelines if
warranted.
In May 2003, the first nationally
accepted pediatric disaster and terror-
ism preparedness recommendations and
treatment guidelines were issued by the
Program for Pediatric Preparedness of
the National Center for Disaster
Preparedness (NCDP). These guide-
lines were based on a National
Consensus Conference sponsored by
the Program for Pediatric Preparedness
and funded by the Agency for
Healthcare Research and Quality and
the EMS for Chidlren Program of the
Health Resources and Services
Administration.  At that time, the only
available treatment for certain types of
nerve gas exposure (predominantly
those with anticholinesterase proper-
ties) was the Mark 1 kit.  
The recommendations were based on
established usage of antidotes for
cholinergic toxicity and were felt to be
both safe and supported by the litera-
ture.  It was stated that the Mark 1
Autoinjector kits (although not
approved for pediatric use) should be
used as initial treatment for children
with severe, life-threatening nerve agent
toxicity for whom IV treatment is not
possible or available, or for whom more
precise IM (mg/kg) dosing would be
logistically impossible. 
It was further felt that while not within
the published dosage range for choliner-
gic toxicity, if a Mark 1 kit was the only
source of atropine and pralidoxime
available after a bona fide exposure it
should be used to treat all children, even
those younger than 3 years old.  
Furthermore, it was felt to be imperative 
to expedite approval of the pediatric
autoinjector kit (which contains both
atropine and an oxime and is designed
for children) that is currently produced
and marketed abroad but not available in
the United States.
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Recommendations and Guidelines: What You Need to Know
The recommendations regarding this new device, a
pediatric dosage AtroPen® and the existing Mark 1
kit (based on the key points listed, information from
the consensus conference and on data that have been
published since that meeting) are summarized
below: 
The Mark 1 kit should remain as the pre-
ferred emergency treatment for children of
any age exposed to a nerve agent with the
dosage based on the previously published
tables, Autoinjector Usage and Recommended
Treatment and Management of Chemical Agents
Used in Terrorism (Consensus Conference
Executive Summary and on pages 3 and 6 of this
document). 
The Mark 1 kit should remain as the pre-
ferred emergency treatment for children
younger than 3 years old after bona fide
nerve agent exposure if it is the only source of
atropine and pralidoxime opperationally fea-
sible or available.
If there are overriding regulations or legislation
that explicitly prohibits agencies from using the
Mark 1 kits for children, then these agencies
should stock and use the pediatric dosage
AtroPen® for the treatment of nerve agent expo-
sure in children.  It is recognized that the pedi-
atric dosage AtroPen® is not equivalent to the
Mark 1 kit and does not treat all children.  As a
result these agencies must also stock and use
atropine in other forms for children weighing
less than 15 pounds and pralidoxime for all chil-
dren (this includes stocking pediatric appropri-





The following additional recommendations regard-
ing needed anticonvulsant treatment (based on the
key points listed above, information from the con-
sensus conference, and on data that have been pub-
lished since that meeting) was made by the Pediatric
Expert Advisory Panel:
The complete treatment of nerve agent
exposure would necessitate the usage of
anticonvulsants. All providers, agencies and
stockpiles in addition to atropine and prali-
doxime must have an anticonvulsant agent in a
formulation and concentration that can be
administered to children in as rapid a fashion
as possible (as available this should include the
usage of auto-injectors).
The anticonvulsants and the dosage guidelines
which can be used to treat children exposed to
a nerve agent who have either a severe expo-




0.05-0.3 mg/kg (max 10 mg) IV or IM
Lorazepam 
0.1 mg/kg IV or IM (max 4 mg)
Midazolam 
0.1-0.2 mg/kg (max 10 mg) IV or IM
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Rationale for Recommendations
The Pediatric Expert Advisory Panel felt the following key points must be considered when making a  determina-
tion regarding the role of the pediatric dosage AtroPen®:
AtroPen® is not equivalent to the current Mark
1 kit because it does not include pralidoxime.
An oxime should be included for appropriate
treatment of nerve agent exposure.
The pediatric dosage AtroPen® does not have
an approved indication for use in children
weighing less than 15 pounds, ie, infants and
young toddlers.
The Mark 1 Kit should be used in children 3
years and older. This represents acceptable
dosage ranges for the first 60 minutes of treat-
ment based on mg per kg dosing (see table
below).  The possible risk of use in children
younger than 3 years old after bona fide nerve





Several stockpiles and organizations, based on
legislation or regulation, may only stock and
use devices for their FDA approved label indi-
cations.
While significant attention has been focused on
the need for atropine and an oxime following a
nerve agent exposure, complete treatment will
require the usage of anticonvulsants.
Previous and recent data has shown that even
when atropine is administered in doses higher
than traditional cholinergic toxicity doses, it


















3-7 yrs 13-25 kg 1 0.08-0.13 24-46
8-14 yrs 26-50 kg 2 0.08-0.13 24-46
>14 yrs >51 kg 3 0.11 or less 35 or less
NOTE: Each Mark 1 kit contains two autoinjectors (0.8 inch needle insertion depth), one each of atropine 2 mg (0.7 ml) and pralidoxime
600 mg (2 ml); while not approved for pediatric use, they should be used as initial treatment in circumstances for children with severe, life-
threatening nerve agent toxicity for whom IV treatment is not possible or available or for whom more precise IM (mg/kg) dosing would be
logistically impossible.  Suggested dosing guidelines are offered; potential excess of initial atropine and pralidoxime dosage for age/weight,
although within general guidelines for recommended total over first 60-90 min of therapy for severe exposures.  This table lists usage of the
Mark 1 kit only down to age 3 based on adherence to recommended dosages for atropine and pralidoxime.  However, if an adult Mark 1 kit
is the only available source of atropine and pralidoxime after a nerve agent exposure, it should not be withheld from even the youngest child.  
Autoinjector Usage
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Nerve agents are liquids under temperate conditions.  The
most commonly discussed agents are VX, GA (Tabun), GB
(Sarin), GD (Soman), and GF.  The more volatile ones consti-
tute both a vapor and a liquid hazard when dispersed. Nerve
agents are organophosphorus cholinesterase inhibitors. They
inhibit butyrylcholinesterase in plasma, acetylcholinesterase
on erythrocytes, and acetylcholinesterase at cholinergic recep-
tor sites in tissue. Some commonly used pesticides (for exam-
ple, the organophosphate [OP] Malathion and the carbamate
Sevin) and some common therapeutic drugs (the carbamates
pyridostigmine [Mestinon] and physostigmine [Antilirium])
also inhibit acetylcholinesterase and can be considered "nerve
agents." However, while the OP pesticides cause the same
biological effects as nerve agents, there are some important
differences in the duration of biological activity and response
to therapy. Acetylcholinesterase (RBC) is most sensitive for
nerve agents while Butyrylcholinesterase (plasma) is more
sensitive for most insecticides
After a nerve agent inhibits the tissue enzyme, the 
enzyme cannot hydrolyze acetylcholine, the neurotransmitter,
at cholinergic receptor sites. Acetylcholine accumulates and
continues to stimulate the affected organ. The clinical effects
from nerve agent exposure are caused by excess acetyl-
choline. 
The normal physiology is an electrical impulse goes
down the nerve.  This impulse causes release of the neuro-
transmitter, acetylcholine (Ach). Then ACh stimulates a
receptor site on an organ and causes the organ to act.  The
ACh is destroyed by acetylcholinesterase (AChE) and once
destroyed no more organ activity is noted.  Organs with
cholinergic receptor sites include the smooth muscles, skele-
tal muscles, central nervous system (CNS), and most exocrine
glands. In addition, cranial efferents and ganglionic afferents
are cholinergic nerves. There are different forms of the recep-
tor for Ach which are categorized by their location and
whether they are stimulated by either nicotine or muscarine.
The muscarinic sites include the smooth muscles and glands.
Nicotine will stimulate other cholinergic sites, known as nico-
tinic sites, which are those in skeletal muscle and ganglia.
Because both the muscarinic (vagal) and nicotinic (pre-gan-
lionic) receptors can affect then heart rate but in different
way, following nerve gent exposure a person may have a
high, low, or normal heart rate. 
Physiology of Nerve Agents
The CNS contains both types of receptors, but the phar-
macology in the CNS is more complex and less well
understood.  We know that an acute, large exposure of a
nerve agent can cause loss of consciousness, seizures,
apnea, and even death.  Whereas an acute but small expo-
sure of a nerve agent can cause minor CNS effects includ-
ing slowness in thinking and decision making, sleep dis-
turbances, poor concentration, emotional problems and
other minor problems.
Treatment of Nerve Agents
The treatment of nerve agents includes decontamina-
tion, the traditional priorities of airway, breathing and cir-
culation, supportive care for the symptoms and adminis-
tration of antidotes.  The goals of the antidotes are to
reverse the underlying process:
Too much acetylcholine
z Block excess acetylcholine
Enzyme inhibited
z Reactivate enzyme
Atropine is a cholinergic blocking agent.  Atropine
and similar compounds block the effects of excess acetyl-
choline more effectively at muscarinic sites than at nico-
tinic sites.  This leads to drying of secretions and reduced
smooth muscle constriction. But atropine does not treat
the skeletal muscle effects and can not treat the miosis,
unless used topically.
The attachment of the agent to the enzyme is permanent
(unless removed by therapy). Erythrocyte enzyme activi-
ty returns at the rate of erythrocyte turnover, about 1 per-
cent per day. Tissue and plasma enzyme activities return
with synthesis of new enzymes. The rate of return of the
tissue and plasma enzymes is not the same, nor is the rate
the same for all tissue enzymes. 
However, the agent can be removed from the enzyme
and the enzyme "reactivated" by several types of com-
pounds, the most useful of which are the oximes. If the
agent-enzyme complex has not "aged," oximes are useful
therapeutically. Aging is a biochemical process by which
the agent-enzyme complex becomes refractory to oxime
reactivation of the enzyme. For most nerve agents, the
aging time is longer than the time within which acute
casualties will be seen, allowing time for treatment.
However, the aging time of the GD-enzyme complex is
about two minutes, and the usefulness of oximes in GD
poisoning is greatly decreased after this period.  
In addition the oximes via the nictonic sites can
increase muscle strength but they have no effect on the
muscarinic sites, thus treating effects of nerve agents





o Airways - constrict
o GI tract - constrict
o Pupils - constrict
z Glands
o Eyes, nose, mouth,
sweat, airways, GI
z Heart, bradycardis (vagal)
z Skeletal muscles
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Antidotes
Atropine is a cholinergic blocking or anticholinergic
compound.  It is extremely effective in blocking the
effects of excess acetylcholine at peripheral mus-
carinic sites.  When small doses (2 mg) are given to
healthy individuals without nerve agent intoxication,
atropine causes mydriasis, a decrease in secretions
(including a decrease in sweating), mild sedation, a
decrease in GI motility, and tachycardia.
Pralidoxime chloride (protopam chloride, 2-
PAMCl) is an oxime.  Oximes attach to the nerve
agent that is inhibiting the cholinesterase and break
the agent-enzyme bond to restore the normal activity
of the enzyme.  Clinically, this is noticeable in organs
that have nicotinic receptors; abnormal activity in
skeletal muscle decreases and normal strength returns.
Nerve Agent Clinical Signs. Vapor Exposure
Mild
z  Eyes: miosis, dim vision, headache
z Nose: rhinorrhea
z Mouth: salivation
z Lungs: Dyspnea (“tightness in the chest”)
z Time of onset: seconds to minutes after   
exposure
Severe
z Same as mild, plus
o Severe breathing difficulty or cessation  
of respiration 
o Generalized muscular twitching, 
weakness, or paralysis 
o Convulsions 
o Loss of consciousness 
o Loss of bladder, bowel control
z Time of onset: seconds to minutes after 
exposure
Nerve Agents Clinical Signs. Liquid on Skin
Mild/moderate
z Muscle twitching at site of exposure 
z Sweating at site of exposure 
z Nausea, vomiting 
z Feeling of weakness 
z Time of onset: 10 minutes to 18 hours after 
exposure 
Severe
z Same as mild/moderate, plus 
o Severe breathing difficulty or cessation 
of breathing 
o Generalized muscular twitching, 
weakness, or paralysis 
o Convulsions 
o Loss of consciousness 
o Loss of bladder and bowel control 
z Time of onset: minutes to an hour after 
exposure
Auto-Injector
Mark 1 kit  Each Mark 1 kit contains two autoinjec-
tors (0.8 inch needle insertion depth), one each of
atropine 2 mg (0.7 ml) and pralidoxime 600 mg (2 ml);
Pediatric Dosage AtroPen® (New Device) Earlier this
year, the FDA approved pediatric dosages of the
AtroPen® (atropine injection), an auto-injector that has
an indication for use in children weighing more than 15
pounds.  The two dosages approved were 0.5 mg of
Atropine for children weighing 15-40 pounds and
1.0mg atropine for children weighing 40-90 pounds.
At this time a device with pediatric dosage of 2-PAM is
not available. These new devices were presented to the
working group for discussion and recommendations for
their use in light of the existing Mark-1 device and the
absence of a pediatric dosage 2-PAM device.   
























































Airway, breathing, circulatory support
Atropine 0.05-0.1 mg/kg IVb, IMc (min
0.1mg, max 5mg), repeatq2-5 min prn for
marked secretions, bronchospasm.
Pralidoxime 25-50 mg/kg IV, IMd (max 1 g
IV; 2 g IM), may repeat within 30-60 min prn,
then again q1h for 1 or 2 doses
prn for persistent weakness, high atropine
requirements.
Diazepam 0.3 mg/kg (max 10 mg) IV,
lorazepam 0.1 mg/kg IV or IM (max 4 mg),
midazolam 0.2 mg/kg (max 10mg) IM prn for
seizures or severe exposure.
Systomatic care
Possibly British anti-lewisite (BAL) 3
mg/kg IM q4-6h for systemic effects of
lewisite in severe cases
Systomatic care
Airway, breathing, circulatory support;
100% oxygen
Sodium bicarbonate prn for metabolic 
acidosis Sodium nitrite (3%)
Dosage (ml/kg)       Estimated Hgb
(g/dl) for average child 
0.27                       10
0.33                       12
0.39                       14
Maximum 10 ml
Sodium thiosulfate
(25%) 1.65 ml/kg (maximum 50 ml)
Skin: erythema, vesicles
Eyes: inflammation
Respiratory tract: inflammation, 
respiratory distress, acute respiratory
distress synrome
Skin: soap and water
Eyes: irrigation (water)
Both: major impact only if done













Eyes, nose, throat irrication
(especially chlorine)























Eye: tearing, pain, blepharospasm




Topical ophthalmics, symptomatic care 
Hours
Immediate Pain
Vapor: fresh air, remove clothes,
wash hair
Liquid: remove clothes, opious




Vapor: miosis, rhinorrhea, dyspnea
Liquid: Diaphoresis, vomiting
Both: coma, paralysis, seizures,
apnea
a Decontamination, especially for patients with significant exposure to nerve agents or vesicants, should be performed by health care providers dressed in adequate personal protective equipment.  For emergency 
department staff, this consists of a non-encapsulated, chemically resistant body suit, boots, and gloves with a full-face air purifier mask/hood.
b Intraosseous route is likely equivalent to intravenous.
c Atropine might have some benefit via endotracheal tube or inhalation, as might aerosolized ipratropium.
d Pralidoxime is reconstituted to 50 mg/ml (1 g in 20 ml water) for IV administration, and the total dose is infused over 30 min, or it may be given by continuous infusion (loading dose 25 mg/kg over 30 min, then 10 
mg/kg/hr).  For IM use, it might be diluted to a concentration of 300 mg/ml (1 g added to 3 ml water - by analogy to the Mark 1 autoinjector concentration), to effect a reasonable volume for injection.
Key: Hgb = hemoglobin; prn = as needed
Recommended Treatment and Management of Chemical Agents Used in Terrorism
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National Center for Disaster Preparedness
722 West 168th Street
New York, NY 10032
www.ncdp.mailman.columbia.edu
The National Center for Disaster Preparedness (NCDP) is a
major national and international resource in disaster and terror-
ism readiness.   While based in the Mailman School of Public
Health, the only accredited school of public health in New York
City, senior investigators, program planners and experts are
selected from Columbia University Medical Center (College of
Physicians & Surgeons, School of Nursing, School of Dental &
Oral Surgery, New York Presbyterian Hospital) as well as from
across the campus of Columbia University including the schools
of Journalism, International Public Affairs, Law, and Teachers
College.  The Center also actively collaborates with: the
Children's Health Fund, the New York City Department of
Health and Mental Hygiene, the Office of Emergency
Management, FEMA, The Center for Disease Control,
Department of Homeland Security, Department of Education
and other key federal, state and city agencies.  The NCDP works
with other academic institutions, as well as advocacy and pub-
lic policy organizations.
Preparedness issues for children, families and special
populations
Hospital and community health systems preparedness 
& curriculum development
Public health workforce competencies
Mental health aspects of disaster preparedness and 
cons quences of terrorism
International collaborations 
Community-based preparedness planning
Individual and family preparedness planning
Technology applications to enhance preparedness
Emerging public health crisis
Public policy implications, costs and impact of 
preparedness planning











The purpose of the Pediatric Expert Advisory Panel (PEAP) is
to discuss, review the current literature, analyze current issues
and to make recommendations for policy and programmatic
action on pediatric terrorism, disaster and public health emer-
gency preparedness.  The resulting information pieces are then
posted to the pediatric section of the National Center for
Disaster Preparedness website at www.ncdp.mailman.colum-
bia.edu and distributed to interested parties.
The Pediatric Expert Advisory Panel  is a major program of  the
National Center for Disaster Preparedness (at the Mailman
School of Public Health), which is composed of public health
experts in epidemiology and program development, clinical
scientists and physicians with expertise in relevant areas,
Pediatric Expert Advisory Panel (PEAP)
healthcare providers from a multitude of fields with pediatric
and other relevant experience, bench scientists, public health
historians, economists, legal and bioethics professionals,
anthropologists, mental health professionals and sociologists,
information technologists, communication and media special-
ists, representatives of national professional organizations and
representatives of federal, state and local governmental agen-
cies.
This Expert Advisory Panel is partially funded by grant number
7 H34 MC00136-01 from the EMSC Program of the
Maternal and Child Health Bureau, Health Resources
Services Administration, Department of Health and
Human Services and by The Children's Health Fund.
Major Areas of Interest & Expertise:
